

1 Prevalence and patient characteristics associated with cardiovascular disease risk  
2 factor screening in UK primary care for people with severe mental illness: An  
3 electronic healthcare record study  
4

5 Authors: Launders N<sup>1</sup>, Jackson CA<sup>2</sup>, Hayes JF<sup>1,3</sup>, John A<sup>4</sup>, Stewart R<sup>5,6</sup>, Iveson MH<sup>7</sup>, Bramon E<sup>1,3</sup>,  
6 Guthrie B<sup>2</sup>, Mercer SW<sup>2</sup>, Osborn DPJ<sup>1,3</sup>.

7  
8 Affiliations

- 9 1. Division of Psychiatry, University College London, London, United Kingdom  
10 2. Usher Institute, The University of Edinburgh, Edinburgh, United Kingdom  
11 3. Camden and Islington NHS Foundation Trust, London, United Kingdom  
12 4. Swansea University Medical School, Swansea University, Swansea, United Kingdom  
13 5. Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, United  
14 Kingdom  
15 6. South London and Maudsley NHS Foundation Trust, London, UK  
16 7. Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh,  
17 United Kingdom

18

19 Manuscript word count: 3,466

20 Abstract word count: 249

21

22 Abstract

23 Background:

24 People with severe mental illness (SMI) are at increased risk of cardiovascular disease (CVD), and  
25 initiatives for CVD risk factor screening in the UK have not reduced disparities.

26 Objectives:

27 To describe the annual screening prevalence for CVD risk factors in people with SMI from April 2000  
28 to March 2018, and to identify factors associated with receiving no screening and regular screening.

29 Methods:

30 We identified adults with a diagnosis of SMI (schizophrenia, bipolar disorder or ‘other psychosis’)  
31 from UK primary care records in Clinical Practice Research Datalink (CPRD). We calculated the annual

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

32 prevalence of screening for blood pressure, cholesterol, glucose, body mass index, alcohol  
33 consumption and smoking status, using multinomial logistic regression to identify factors associated  
34 with receiving no screening and complete screening.

#### 35 Results:

36 Of 216,136 patients with SMI, 55% received screening for all six CVD risk factors at least once follow-  
37 up and 35% received all six within a one-month period. Changes in screening prevalence coincided  
38 with changes in incentivisation of screening. In 2014-2018, men, people with a diagnosis of 'other  
39 psychoses', or with missing ethnicity were more likely to have received no screening.

#### 40 Conclusions:

41 The low proportion of people with SMI receiving regular comprehensive CVD risk factor screening is  
42 concerning. Screening needs to be embedded as part of broad physical health checks to ensure the  
43 health needs of people with SMI are being met. If we are to improve cardiovascular health,  
44 interventions are needed where risk of receiving no screening or not receiving regular screening is  
45 highest.

#### 46 What is already known on this topic

- 47 • The prevalence of CVD risk factor screening in primary care increased with the introduction  
48 of an incentivisation scheme and when incentivisation for screening for specific CVD risk  
49 factors is removed the screening decreases.

#### 50 What does this study add?

- 51 • Few patients received regular screening for all six CVD risk factors considered, and both  
52 screening prevalence and risk of receiving no screening varied depending on patient  
53 characteristics.

- 54       • Only 35% of patients ever received screening for all six CVD risk factors considered in a one-  
55           month period, suggesting that screening is not often being done as part of a physical health  
56           check.

57   **How this study might affect research, practice or policy**

- 58       • Clinicians should be aware that some sub-groups of patients with SMI are less likely to  
59           receive screening, and the importance of providing screening as part of a regular,  
60           comprehensive physical health check.

61   Background

62   People with severe mental illnesses (SMI), such as schizophrenia, bipolar disorder or other psychotic  
63   illnesses, are at increased risk of many physical health conditions<sup>1,2</sup>. People with SMI have 1.5 to 2.5  
64   times the risk of cardiovascular disease (CVD) compared to the general population and an increased  
65   risk of death from CVD<sup>3-7</sup>. They also have a higher prevalence of CVD risk factors, such as smoking,  
66   obesity and diabetes<sup>1,8-10</sup>, which is compounded by cardiometabolic side effects of antipsychotic  
67   medication<sup>11</sup>, and sociodemographic risk factors<sup>12,13</sup>.

68   In recognition of physical health disparities in people with SMI, financial incentivisation of physical  
69   health checks for people with SMI in primary care was introduced in the UK in 2004 through the  
70   Qualities and Outcomes Framework (QOF)<sup>14</sup>. QOF initially incentivised a review of physical health,  
71   with incentivisation of screening for individual CVD risk factors introduced in 2011. While blood  
72   pressure and alcohol consumption screening have been consistently incentivised since 2011 and  
73   smoking status has been incentivised since 2008, cholesterol, glucose and BMI screening have been  
74   less consistently incentivised (see Table S1 for QOF changes related to SMI). Additionally, from 2014  
75   the measures incentivised differed across the constituent countries of the UK, and Scotland and  
76   Wales abolished QOF in 2016 and 2019 respectively.

77 Several studies have shown an increase in recording of CVD risk factors following the introduction of  
78 QOF in people with SMI<sup>15-18</sup>, and a recent cohort study found that in England, removal of cholesterol  
79 and BMI as incentivised indicators resulted in a decrease in recording of these risk factors compared  
80 to blood pressure recording<sup>19</sup>. However, there is a lack of evidence regarding long term trends in  
81 screening prevalence for the six CVD risk factors currently included in the NHS England Physical  
82 Health Check for SMI, and patient characteristics associated with receiving screening. In order to  
83 identify unmet need and improve the health of people with SMI, it is important to understand  
84 whether incentivisation drives increases in screening in all patients with SMI, and to identify which  
85 individuals may be at risk of not being screened.

86 Objective: To investigate the long-term trends and patient characteristics associated with receipt of  
87 comprehensive CVD risk factor screening: blood pressure, cholesterol, glucose screening, BMI  
88 measurement, alcohol consumption and smoking status.

## 89 Methods

### 90 Study design

91 We used Clinical Practice Research Datalink (CPRD) GOLD and Aurum databases to patients with SMI.  
92 These databases contain deidentified healthcare records for patients registered with primary care  
93 practices in the UK and are broadly representative of the UK population<sup>20,21</sup>. Our protocol was pre-  
94 registered (<https://osf.io/czetb/>). We investigated annual screening prevalence of six CVD risk factors  
95 at the population level. We then investigated screening patterns at an individual level and patient  
96 characteristics associated with receipt of screening.

### 97 Population

98 We identified patients aged over 18 with a diagnosis of SMI (defined as schizophrenia, bipolar  
99 disorder or other non-organic psychosis) recorded in primary care records. Entry to the cohort was  
100 the latest of SMI diagnosis date, registration at primary care practice, or 1 April 2000. Exit was the

101 earliest of death, leaving the primary care practice, 100<sup>th</sup> birthday, or 31 March 2018. Patients did  
102 not re-enter the cohort following exit.

103 Patients were required to have at least one year of follow-up following entry into the cohort to allow  
104 time for screening to be recorded. In line with QOF reporting rules patients had to be registered with  
105 their primary care practice for the last three months of a financial year in order to be eligible for  
106 screening in that year. In the analysis of factors associated with CVD risk factor screening, we  
107 stratified the follow-up time into three periods; April 2004- March 2011; April 2011 – March 2014;  
108 April 2014 – March 2018, based on major changes to the QOF incentivisation programme (Table S1).  
109 Patients were included in each period if they were eligible for screening for at least two financial  
110 years of that period.

#### 111 [Covariates](#)

112 We defined the following covariates *a priori*:

113 We defined sex, primary care practice and country of primary care practice as recorded in CPRD, and  
114 prescription of antipsychotics or mood stabilisers (lithium, sodium valproate or lamotrigine) based on  
115 recorded prescriptions issued in primary care.

116 We defined age as under 40 years or 40 years and older based on year of birth, chosen because  
117 cholesterol and blood glucose screening incentivisation was limited to those 40 years and over<sup>22</sup>. In  
118 multinomial logistic regression models, we included age at start of follow-up as a continuous variable  
119 and reported effect size as odds ratios (OR) per 10-year increase in age.

120 We defined ethnicity as recorded in primary care records and grouped as per the UK 2011 Census<sup>23</sup>.

121 We defined specific SMI diagnosis was defined as the most recently recorded of schizophrenia,  
122 bipolar disorder or other non-organic psychotic illness.

123 We defined presence on other QOF registers which incentivise CVD risk factor screening as having a  
124 Read code used in the 2017-2018 QOF incentivisation for any of: atrial fibrillation, coronary heart

125 disease, hypertension, peripheral artery disease, stroke or diabetes. Exception reporting was defined  
126 as ever having a Read code that would remove a patient from the incentivisation denominator for  
127 the mental health domain (i.e. deemed unsuitable, withdrew consent, or didn't respond to  
128 invitations for screening).

#### 129 Outcomes

130 We investigated screening of six individual CVD risk factors (cholesterol, blood glucose, blood  
131 pressure, BMI, smoking status and alcohol consumption screening), and a composite outcome of all  
132 six. For glucose, we included codes for blood glucose or HbA1C tests or values, but excluded urine  
133 testing. For cholesterol, we included any screening code or value. For blood pressure, we included  
134 screening codes or values for either diastolic or systolic blood pressure. For BMI we included BMI  
135 values, BMI calculated from height and weight, and screening codes. For smoking and alcohol status  
136 we included any screening code. Further details on the prevalence of CVD risk factors in this cohort is  
137 available on the DATAMIND website (<https://datamind.org.uk/data/harmonised-data/smi-cohorts/>)  
138 and code lists used to define the population, covariates and outcomes are available in the HDR UK  
139 phenotype library (Table S2).

140 In the individual-level analysis of factors associated with CVD risk factor screening, in each time  
141 period a patient was considered to have 'always complete screening' if they received screening for all  
142 six CVD risk in each financial year in the time period that they were active. Irregular screening was  
143 defined as any frequency between 'always complete screening' and receiving no screening.

#### 144 Statistical analysis

145 We calculated the annual prevalence of recorded screening of each of the six CVD risk factors,  
146 stratifying by the aforementioned covariates. We calculated the proportion of patients receiving all  
147 six CVD risk factors ever during follow-up, ever within a one-month period, and for each financial  
148 year.

149 We conducted multinomial logistic regression analyses to assess patient factors associated with  
150 receiving 'always complete' CVD risk factor screening and receiving no screening in each of the three  
151 time periods, compared to receiving irregular screening.

152 We mutually adjusted for all covariates in the models, with the exception of primary care practice  
153 which was used as a clustering term in the calculation of sandwich standard errors. We additionally  
154 adjusted for the time since SMI diagnosis, time since primary care practice registration, year of end  
155 of follow-up and total follow-up time. Analysis was performed in R and R Studio and reported in line  
156 with the RECORD checklist<sup>24</sup>.

#### 157 Missing data

158 Missing ethnicity was included as a separate category as those with missing ethnicity are different to  
159 those with a recorded ethnicity with respect to healthcare access and engagement. For all diagnostic  
160 and screening variables, we deemed absence of a code to indicate an absence of diagnosis or  
161 screening. We excluded 122 patients who were missing geographical data from the analysis.

#### 162 Sensitivity analyses

163 In *a priori* sensitivity analysis we limited the population to patients resident in England with available  
164 deprivation data (English Index of Multiple Deprivation (IMD) quintiles). In *post-hoc* analysis we  
165 limited the model to patients who were active for the whole of the follow-up period due to the  
166 strong effect of follow-up time on the completeness of screening.

#### 167 PPI involvement

168 Lived experience advisors from the DATAMIND Super Research Advisory Group  
169 (<https://datamind.org.uk/patients-and-public/the-super-research-advisory-group/>) and UCL Mental  
170 Health Data Science PPIE group commented on the protocol and provided input into the  
171 interpretation of results.

## 172 Findings

173 We identified 312,471 patients with a diagnostic code for SMI at any time, of whom 216,136 had a  
174 diagnosis of SMI before the end of follow-up, were over the age of 18 years, with at least one year of  
175 registration and without missing geographic data (Figure S1). Patients had a median of 4.85 (IQR:  
176 2.43, 9.72) years of follow-up (Table 1).

177 *Table 1: Characteristics of the cohort of patients with severe mental illness in CPRD, n=216,136*

Characteristic		n (%) / median [IQR]
<b>Age at SMI diagnosis (median [IQR])</b>		35 [26, 48]
<b>Age at start of follow-up (median [IQR])</b>		44 [33, 59]
<b>Age at end of follow-up (median [IQR])</b>		52 [39, 68]
<b>Follow-up time<sup>a</sup> (median [IQR])</b>		4.85 [2.43, 9.72]
<b>Sex, n (%)</b>	Male	111,655 (51.7)
	Female	104,481 (48.3)
<b>Ethnicity, n (%)</b>	Asian	7,679 (3.6)
	Black	9,979 (4.6)
	Mixed	2,733 (1.3)
	Other	4,199 (1.9)
	White	110,673 (51.2)
	Missing	80,873 (37.4)
<b>Country, n (%)</b>	England	186,880 (86.5)
	Northern Ireland	3,405 (1.6)
	Scotland	14,010 (6.5)
	Wales	11,841 (5.5)
<b>Most recent SMI diagnosis, n (%)</b>	Schizophrenia	73,753 (34.1)
	Bipolar disorder	68,921 (31.9)
	Other psychoses	73,462 (34.0)
<b>Ever exception reported, n (%)</b>		59,736 (27.6)
<b>Ever on another CVD QOF register<sup>b</sup>, n (%)</b>		64,295 (29.8)
<b>Ever prescribed antipsychotics, lithium, sodium valproate or lamotrigine, n (%)</b>		173,669 (80.3)
<b>Died during follow-up<sup>a</sup>, n (%)</b>		31,210 (14.4)
<b>Age at death (median [IQR])</b>		75.49 [62.44, 84.74]

178 SMI: Severe Mental Illness; CVD: cardiovascular disease; IQR: interquartile range; QOF: Quality and Outcomes  
179 Framework

180 a: Follow-up starts at the latest of 01/04/2000, primary care practice registration, SMI diagnosis or age 18 and  
181 ends at the earliest of death, leaving the primary care practice, age 100 or last data collection by CPRD.

182 b: Defined as presence on QOF register for atrial fibrillation, coronary heart disease, hypertension, peripheral  
183 artery disease, stroke or diabetes.

184



185 Population-level analysis of cardiovascular disease risk factor screening

186 The prevalence of smoking and blood pressure screening increased steadily during the study period.


187 In contrast, for alcohol, BMI, cholesterol and glucose screening the prevalence of screening increased

188 sharply in 2011-2012 following the introduction of incentivisation of individual CVD risk factors. For

189 BMI, cholesterol and glucose screening the prevalence decreased rapidly from 2013-2014 to 2014-

190 2015, coinciding with the withdrawal of financial incentives (Figure 1, Table S3).

191 *Figure 1: Prevalence of cardiovascular risk factor screening in people with severe mental illness, in the*  
192 *primary care setting in the UK by financial year*



193

194 \*Dotted lines represent years where: incentivisation for 'physical health checks' (no specific required content)  
195 was introduced as one measure (2004-2005); all measures were individually incentivised (2011-2012); and only

196 alcohol, blood pressure and smoking were individually incentivised in England, while incentivisation differed in  
197 Northern Ireland, Scotland and Wales (2014-2015). BMI: Body mass index

198

199 These broad patterns remained when stratified by most patient characteristics (Figures S2-S10).

200 However, the increase in cholesterol and glucose screening in 2011-2013 was primarily observed in

201 those aged 40 years or older (Figure S2), the population incentivised at the time. While the

202 prevalence of screening increased for all countries from 2000 to 2014, from 2014 to 2018 (a period

203 of diverging incentivisation across the four nations) the pattern was less consistent (Figure S3).

204 Screening for all CVD risk factors was lowest in those with a diagnosis of 'other psychoses' (Figure

205 S4), men (Figure S5), those not on another QOF register (Figure S6) and those not on antipsychotics

206 or mood stabilisers (Figure S7). Screening prevalence for smoking was highest in patients of White or

207 Mixed ethnicity, and screening of other CVD risk factors was highest in patients of Asian ethnicity

208 (Figure S7).

209 Individual-level factors associated with receiving 'always complete' or no CVD risk factor

210 screening

211 Almost all patients (93.9%) received screening for at least one of the six CVD risk factors at some

212 point during follow-up. However, only half (54.8%) received screening for all six CVD risk factors at

213 least once (Table 2), and this occurred within a one-month period at least once for only 34.8% of

214 patients.

215 Table 2: Proportion of patients with severe mental illness ever receiving screening for: each cardiovascular disease (CVD) risk factor; any of the six CVD risk  
 216 factors; and all six CVD risk factors, stratified by covariates, 2000-2018

	n	Cholesterol, n(%)	Glucose, n(%)	Blood pressure, n(%)	BMI, n(%)	Smoking, n(%)	Alcohol, n(%)	Any screening measure ever, n(%)	Ever received all 6 measures, n(%)	
<b>All</b>	216,136	136,897 (63.3)	151,652 (70.2)	189,844 (87.8)	168,378 (77.9)	190,967 (88.4)	172,441 (79.8)	202,900 (93.9)	118,351 (54.8)	
<b>Age at start of follow-up</b>	Under 40	85,094	42,548 (50.0)	49,781 (58.5)	70,464 (82.8)	65,073 (76.5)	75,353 (88.55)	67,778 (79.7)	78,660 (92.4)	37,467 (44.0)
	40+	131,042	94,349 (72.0)	101,871 (77.7)	119,380 (91.1)	103,305 (78.8)	115,614 (88.2)	104,663 (79.9)	124,240 (94.8)	80,884 (61.7)
<b>Sex</b>	Male	111,655	68,285 (61.2)	73,664 (66.0)	94,744 (84.6)	85,708 (76.8)	98,423 (88.1)	89,405 (80.1)	103,497 (92.7)	59,466 (53.3)
	Female	104,481	68,612 (65.7)	77,988 (74.6)	95,100 (91.0)	82,670 (79.1)	92,544 (88.6)	83,036 (79.5)	99,403 (95.1)	58,885 (56.4)
<b>Ethnicity</b>	Asian	7,679	5,896 (76.8)	6,234 (81.2)	7,192 (93.7)	6,886 (89.7)	7,317 (95.3)	7,079 (92.2)	7,533 (98.1)	5,457 (71.1)
	Black	9,979	6,966 (69.8)	7,386 (74.0)	9,189 (92.1)	8,684 (87.0)	9,410 (94.3)	8,933 (89.5)	9,697 (97.2)	6,366 (63.8)
	Mixed	2,733	1,755 (64.2)	1,885 (69.0)	2,472 (90.5)	2,344 (85.8)	2,610 (95.5)	2,455 (89.8)	2,677 (98.0)	1,575 (57.6)
	Other	4,199	2,652 (63.2)	2,969 (70.7)	3,710 (88.4)	3,264 (77.7)	3,860 (91.9)	3,382 (80.5)	4044 (96.3)	2,222 (52.9)
	White	110,673	80,734 (72.9)	86,716 (78.4)	103,788 (93.8)	97397 (88.0)	106,716 (96.4)	100,784 (91.1)	109,203 (98.7)	73,018 (66.0)
	Missing	80,873	38,894 (48.1)	46,462 (57.5)	63,493 (78.5)	49,803 (61.6)	61,054 (75.5)	49,808 (61.6)	69,740 (86.2)	29,677 (36.7)
<b>Country</b>	England	186,880	117,627 (62.9)	130,688 (69.9)	164,352 (87.9)	145,296 (77.7)	165,068 (88.3)	149,262 (79.9)	175,491 (93.9)	101,644(54.4)
	Northern Ireland	3,405	2,546 (74.8)	2,716 (79.8)	3,069 (90.1)	2,816 (82.7)	3,053 (89.7)	2,797 (82.1)	3,220 (94.6)	2,208 (64.8)
	Scotland	14,010	8,975 (64.1)	9,422 (67.3)	11,994 (85.6)	10,813 (77.2)	122,27 (87.3)	10,835 (77.3)	12,971 (92.6)	7,708 (55.0)
	Wales	11,841	7,749 (65.4)	8,826 (74.5)	10,429 (88.1)	9,453 (79.8)	10,619 (89.7)	9,547 (80.6)	11,218 (94.7)	6,791 (57.35)
<b>SMI diagnosis</b>	Schizophrenia	73,753	47,869 (64.9)	51,813 (70.3)	64,368 (87.3)	57,927 (78.5)	64,902 (88.0)	58,788 (79.7)	68,449 (92.8)	42,132 (57.1)
	Bipolar disorder	68,921	46,587 (67.6)	51,431 (74.6)	62,488 (90.7)	56,195 (81.5)	62,394 (90.5)	56,951 (82.6)	65,874 (95.6)	40,529 (58.8)
	Other psychoses	73,462	42,441 (57.7)	48,408 (65.9)	62,988 (85.7)	54,256 (73.9)	63,671 (86.7)	56,702 (77.2)	68,577 (93.4)	35,690 (48.6)
<b>Ever exception reported</b>	No	156,376	96,387 (61.6)	107,467 (68.7)	135,588 (86.7)	118,881 (76.0)	134,324 (85.9)	120,774 (77.2)	144,623 (92.5)	82,463 (52.73)
	Yes	59,760	40528 (67.8)	44203 (74.0)	54277 (90.8)	49,497 (82.8)	56667 (94.8)	51691 (86.5)	58,277 (97.5)	35,888 (60.05)
<b>Ever other QOF<sup>a</sup></b>	No	151,841	81,417 (53.6)	94,124 (62.0)	127,397 (83.9)	113,031 (74.4)	131,518 (86.6)	117,208 (77.2)	139,715 (92.0)	69,972 (46.08)
	Yes	64,295	55,480 (86.3)	57,528 (89.5)	62,447 (97.1)	55,347 (86.1)	59,449 (92.5)	55,233 (85.9)	63,185 (98.2)	48,379 (75.2)

		n	Cholesterol, n(%)	Glucose, n(%)	Blood pressure, n(%)	BMI, n(%)	Smoking, n(%)	Alcohol, n(%)	Any screening measure ever, n(%)	Ever received all 6 measures, n(%)
<b>Ever prescribed antipsychotics /mood stabilisers</b>	No	42,467	19,178 (45.2)	22,071 (52.0)	33,028 (77.8)	28,426 (66.9)	34,662 (81.6)	29,940 (70.5)	37,439 (88.2)	15,399 (36.3)
	Yes	173,669	117,719 (67.8)	129,581 (74.6)	156,816 (90.3)		156,305 (90.0)	142,501 (82.1)		
						139,952 (80.6)			165,461 (95.3)	102,952 (59.3)

217 SMI: Severe Mental Illness; BMI: Body mass index; QOF: Quality and Outcomes Framework

218 a: Defined as presence on QOF register for atrial fibrillation, coronary heart disease, hypertension, peripheral artery disease, stroke or diabetes.

219 In the period prior to all six CVD risk factors being incentivised (2004-2011) 1.7% of patients received  
220 'always complete' screening (i.e. all six CVD risk factors each financial year that they were active  
221 between 2004 and 2011). This increased to 14.8% during the period of individual incentivisation  
222 (2011-2014) and decreased to 8.3% following that (2014-2018; Table 3).

223 The odds of receiving no screening in the 2014-2018 and 2011-2014 periods were higher for men,  
224 patients of 'other' or missing ethnicity (compared to White ethnicity) and those who had been  
225 exception reported from QOF, even after mutual adjustment for covariates (Tables 3 & 4). Conversely,  
226 those on other QOF registers which incentivise screening or who had been prescribed antipsychotics  
227 or mood stabilisers were less likely to receive no screening in each time period (Tables 3 & 4). In  
228 adjusted analyses, compared to patients in England, patients resident in Scotland or Wales were less  
229 likely to receive no screening in the 2011-2014 period, but more likely to receive no screening in the  
230 2014-2018 period when both countries reduced incentives in varying ways (Table 4, Table S1).

231 In the 2014-2018 period only, older age was associated with lower odds of receiving no screening  
232 (OR per 10-year increase in age: 0.86; 95%CI:0.83-0.90), and compared to bipolar disorder, a  
233 diagnosis of 'other psychoses' was associated with higher odds of receiving no screening (Table 4). In  
234 the 2011-2014 period only, compared to White ethnicity, Black ethnicity was associated with higher  
235 odds of receiving no screening (OR:1.31; 95%CI:1.03-1.67).

236

237 Table 3: Unadjusted multinomial logistic regression for the odds ratio of always receiving complete screening<sup>a</sup> or receiving no screening compared to  
 238 irregular screening, among people with severe mental illness, during two time periods

		April 2011 – March 2014 (n=85,274)		April 2014 – March 2018 (n=94,216)	
Reference: Irregular screening		Complete (n=12,616, 14.79%)	None (n=3,204, 3.76%)	Complete (n=7,771, 8.25%)	None (n=2,092, 2.22%)
		OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
<b>Age at start of follow-up</b>	Per 10-year increase	<b>1.26 (1.24-1.27)</b>	1.00 (0.95-1.06)	<b>1.27 (1.24-1.28)</b>	<b>0.82 (0.79-0.94)</b>
<b>Sex (ref female)</b>	Male	1.03 (0.98-1.07)	<b>1.58 (1.46-1.72)</b>	<b>1.09 (1.04-1.15)</b>	<b>1.93 (1.75-2.12)</b>
<b>Ethnicity (ref White)</b>	Asian	<b>1.13 (1.00-1.28)</b>	1.02 (0.81-1.30)	<b>1.54 (1.34-1.78)</b>	0.82 (0.62-1.09)
	Black	<b>0.81 (0.71-0.92)</b>	<b>1.60 (1.27-2.02)</b>	<b>1.18 (1.01-1.37)</b>	<b>1.35 (1.08-1.68)</b>
	Mixed	<b>0.65 (0.53-0.78)</b>	1.24 (0.85-1.80)	0.83 (0.67-1.01)	0.89 (0.58-1.36)
	Other	<b>0.68 (0.57-0.81)</b>	<b>2.43 (1.88-3.13)</b>	<b>0.73 (0.58-0.93)</b>	<b>2.12 (1.61-2.79)</b>
	Missing	<b>0.73 (0.66-0.80)</b>	<b>4.76 (3.92-5.78)</b>	<b>0.68 (0.61-0.75)</b>	<b>2.62 (2.33-2.95)</b>
<b>Country (ref England)</b>	Northern Ireland	1.04 (0.69-1.57)	<b>0.55 (0.37-0.79)</b>	<b>0.58 (0.35-0.94)</b>	1.31 (0.90-1.90)
	Scotland	<b>1.36 (1.17-1.59)</b>	0.85 (0.68-1.07)	1.06 (0.86-1.30)	<b>3.02 (2.59-3.52)</b>
	Wales	<b>0.66 (0.55-0.79)</b>	0.80 (0.61-1.58)	<b>0.52 (0.43-0.65)</b>	<b>1.95 (1.57-2.42)</b>
<b>SMI diagnosis (ref bipolar disorder)</b>	Schizophrenia	<b>1.26 (1.20-1.32)</b>	<b>1.31 (1.19-1.45)</b>	<b>1.38 (1.30-1.48)</b>	<b>1.17 (1.04-1.32)</b>
	Other psychoses	<b>0.83 (0.78-0.87)</b>	<b>1.44 (1.27-1.63)</b>	<b>0.87 (0.82-0.93)</b>	<b>1.82 (1.63-2.03)</b>
<b>In period variables<sup>d</sup></b>	Exception reported <sup>b</sup>	<b>0.37 (0.35-0.39)</b>	<b>1.46 (1.19-1.80)</b>	<b>0.45 (0.42-0.48)</b>	<b>2.14 (1.92-2.38)</b>
	Other QOF register <sup>c</sup>	<b>2.30 (2.17-2.42)</b>	<b>0.28 (0.25-0.31)</b>	<b>3.71 (3.39-4.07)</b>	<b>0.28 (0.52-0.30)</b>
	On antipsychotics/mood stabilisers	<b>2.05 (1.93-2.18)</b>	<b>0.14 (0.13-0.16)</b>	<b>2.14 (1.97-2.32)</b>	<b>0.21 (0.19-0.23)</b>
	Years since diagnosis	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)
	Years since registration	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)
	Years of follow-up	1.00 (1.00-1.00)	0.998 (0.998-0.999)	1.00 (1.00-1.00)	0.999 (0.999-1.00)
<b>Year of end of record in period (ref final year)<sup>e</sup></b>	Year 2	<b>0.00 (0.00-0.00)</b>	<b>0.00 (0.00-0.00)</b>	0.43 (0.57-3.15)	<b>5.07 (1.52-16.87)</b>
	Year 3	NA	NA	<b>1.66 (1.51-1.83)</b>	<b>2.50 (2.19-2.86)</b>

239 OR: Odds ratio; 95% CI: 95% confidence interval; ref: Reference category; SMI: Severe Mental Illness; QOF: Quality and Outcomes Framework

240 a: Complete screening was defined as screening of all six cardiovascular risk factors for each year that the patient is active

241 b: Exception reported from mental health measures

- 242 c: Defined as presence on QOF register for atrial fibrillation, coronary heart disease, hypertension, peripheral artery disease, stroke or diabetes.
- 243 d: In period variables measured cross-sectionally, up to the end of the period of interest
- 244 e: Defined as the year a patient ends follow-up. For the 2014-2018 cohort, year two is 2015-2016, year 3 is 2016-2017 and the final year is 2017-2018. For the 2011-2014
- 245 cohort year 2 is 2012-2013 and the final year is 2013-2014.
- 246 Note: Patients could be present in both time periods. The total number of unique patients is 119,976

247 Men were both more likely to have received no screening, and to have always received complete  
248 screening than women in both time periods. Men, older patients, those of Asian ethnicity (compared  
249 to those of White ethnicity), with a diagnosis of schizophrenia (compared to bipolar disorder),  
250 prescribed antipsychotics or mood stabilisers, on a QOF register that incentivised CVD risk factor, and  
251 who were never exception reported were more likely to always receive complete screening in all time  
252 periods, in unadjusted and adjusted models (Table 3 & 4 and Table S4). Patients of Black (versus  
253 White) ethnicity were more likely to always have complete screening in the 2014-2018 period only  
254 (OR:1.39; 95%CI:1.19-1.62, Table 4).

255 Characteristics associated with receipt of screening differed for individual CVD risk factors. For  
256 example, in the 2014-2018 period men were more likely to have received regular glucose, cholesterol  
257 or smoking screening, but women were more likely to have received regular blood pressure  
258 screening. Patients of Black ethnicity were less likely to have received no screening for glucose,  
259 cholesterol, and BMI, had similar odds of alcohol and blood pressure screening but were more likely  
260 to have received no smoking screening than patients of White ethnicity (Table S5).

261 *Sensitivity analysis: Investigating the effect of deprivation and follow-up time*

262 Limiting the population to those with available deprivation data or those with complete follow-up for  
263 each period did not alter most findings (Table S6-S7). Deprivation was not associated with receiving  
264 always complete or no screening, except for in the 2014-2018 period, where those in the most  
265 deprived quintile were less likely to have received no screening than those in the least deprived  
266 quintile (OR:0.74; 95%CI:0.56-0.99, Table S6).



267 Table 4: Adjusted multinomial logistic regression<sup>a</sup> for the odds ratio of always receiving complete screening<sup>a</sup> or receiving no screening compared to irregular  
 268 screening, among people with severe mental illness, during two time periods

		April 2011 – March 2014 (n=85,274)		April 2014 – March 2018 (n=94,216)	
Reference: Irregular screening		Complete (n=12,616, 14.79%)	None (n=3,204, 3.76%)	Complete (n=7,771, 8.25%)	None (n=2,092, 2.22%)
<b>Age at start of follow-up</b>	Per 10-year increase	<b>1.18 (1.17-1.21)</b>	1.01 (0.96-1.05)	<b>1.15 (1.14-1.17)</b>	<b>0.86 (0.83-0.90)</b>
<b>Sex (ref female)</b>	Male	<b>1.24 (1.19-1.30)</b>	<b>1.31 (1.21-1.43)</b>	<b>1.33 (1.26-1.41)</b>	<b>1.41 (1.27-1.56)</b>
<b>Ethnicity (ref White)</b>	Asian	<b>1.24 (1.09-1.41)</b>	1.00 (0.78-1.29)	<b>1.75 (1.51-2.04)</b>	0.88 (0.66-1.17)
	Black	0.93 (0.82-1.06)	<b>1.31 (1.03-1.67)</b>	<b>1.39 (1.19-1.62)</b>	1.23 (0.98-1.55)
	Mixed	<b>0.81 (0.67-0.97)</b>	1.02 (0.69-1.50)	1.04 (0.85-1.28)	0.83 (0.54-1.28)
	Other	<b>0.77 (0.65-0.92)</b>	<b>2.56 (1.98-3.31)</b>	0.83 (0.67-1.03)	<b>1.66 (1.29-2.15)</b>
	Missing	<b>0.69 (0.63-0.76)</b>	<b>5.26 (4.34-6.38)</b>	<b>0.70 (0.63-0.78)</b>	<b>2.15 (1.89-2.44)</b>
<b>Country (ref England)</b>	Northern Ireland	1.14 (0.75-1.73)	<b>0.33 (0.22-0.48)</b>	<b>0.60 (0.38-0.97)</b>	1.17 (0.78-1.74)
	Scotland	<b>1.56 (1.32-1.86)</b>	<b>0.67 (0.53-0.84)</b>	1.15 (0.93-1.44)	<b>2.88 (2.43-3.41)</b>
	Wales	<b>0.81 (0.67-0.97)</b>	<b>0.48 (0.36-0.64)</b>	<b>0.65 (0.54-0.79)</b>	<b>1.51 (1.21-1.88)</b>
<b>SMI diagnosis (ref bipolar disorder)</b>	Schizophrenia	<b>1.27 (1.20-1.34)</b>	0.99 (0.89-1.10)	<b>1.30 (1.22-1.39)</b>	0.90 (0.79-1.03)
	Other psychoses	<b>0.92 (0.88-0.97)</b>	1.05 (0.94-1.17)	0.96 (0.90-1.02)	<b>1.22 (1.09-1.37)</b>
<b>In period variables<sup>d</sup></b>	Exception reported <sup>b</sup>	<b>0.38 (0.36-0.41)</b>	<b>1.26 (1.08-1.47)</b>	<b>0.47 (0.44-0.51)</b>	<b>1.69 (1.51-1.89)</b>
	Other QOF register <sup>c</sup>	<b>1.93 (1.82-2.04)</b>	<b>0.31 (0.28-0.35)</b>	<b>3.21 (2.93-3.53)</b>	<b>0.35 (0.31-0.39)</b>
	On antipsychotics/mood stabilisers	<b>1.89 (1.77-2.01)</b>	<b>0.17 (0.15-0.19)</b>	<b>1.95 (1.80-2.11)</b>	<b>0.24 (0.21-0.26)</b>
	Years since diagnosis	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)
	Years since registration	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)
	Years of follow-up	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)
<b>Year of end of record in period (ref final year)<sup>e</sup></b>	Year 2	<b>0.00 (0.00-0.00)</b>	<b>0.00 (0.00-0.00)</b>	0.28 (0.04-2.14)	<b>4.67 (1.05-20.71)</b>
	Year 3	NA	NA	<b>1.35 (1.21-1.50)</b>	<b>2.47 (2.10-2.90)</b>

269 OR: Odds ratio; 95% CI: 95% confidence interval; ref: Reference category; SMI: Severe Mental Illness; QOF: Quality and Outcomes Framework

270 a: Multinomial logistic regression comparing patients receiving no screening or receiving complete screening (all six cardiovascular risk factors for each year that the patient  
 271 is active in the time period) to those who were irregularly screened, with mutual adjustment for all covariates.

272 b: Exception reported from mental health measures

273 c: Defined as presence on QOF register for atrial fibrillation, coronary heart disease, hypertension, peripheral artery disease, stroke or diabetes.

274 d: In period variables measured cross-sectionally, up to the end of the period of interest  
275 e: Defined as the year a patient ends follow-up. For the 2014-2018 cohort, year two is 2015-2016, year 3 is 2016-2017 and the final year is 2017-2018. For the 2011-2014  
276 cohort year 2 is 2012-2013 and the final year is 2013-2014.  
277 Note: Patients could be present in both time periods. The total number of unique patients is 119,976

## 278 Discussion

279 We found that cardiovascular risk factor screening prevalence varied by individual CVD risk factor,  
280 over time, and by patient characteristics. Our findings suggest that patient characteristics and  
281 financial incentivisation influence screening prevalence of individual CVD risk factors, the likelihood  
282 of receiving screening for all six CVD risk factors annually, and risk of receiving no screening.  
283 However, as the patient characteristics associated with increased risk of receiving no screening  
284 change over the study periods, it is likely that the groups most at risk of missing screening are  
285 dynamic and dependent on which measures are incentivised. Between 2014 and 2018, men, younger  
286 patients and those without pre-existing conditions, not prescribed antipsychotics or mood stabilisers,  
287 of missing or 'other' ethnicity, or with a diagnosis of 'other psychoses' had an elevated risk of  
288 receiving no screening.

289 We found a sharp increase in CVD risk factor screening in 2011, most notable for alcohol, BMI,  
290 cholesterol and glucose screening, and coinciding with the introduction of incentivisation of all six of  
291 the CVD risk factors studied. The subsequent reduction in prevalence of glucose, cholesterol and BMI  
292 screening in 2014 coincides with the removal of these measures from incentivisation in England and  
293 Northern Ireland, a pattern not seen in the screening prevalence of CVD risk factors which remained  
294 incentivised in these countries<sup>22</sup>. This is in line with a recent study by Matias et al, which found a  
295 significant reduction in screening for cholesterol and BMI in this period compared to blood pressure  
296 in patients with SMI<sup>19</sup>, and studies in the general population which show a decrease in target  
297 achievement when incentivisation is withdrawn<sup>25</sup>.

## 298 Strengths and limitations

299 The large population size allowed us to stratify results by a range of patient characteristics, while the  
300 representative nature of CPRD data makes these results generalisable to the UK for this time period,  
301 although with notable differences across the four nations of the UK from 2014. Focusing on  
302 longitudinal screening at an individual level, as well as screening prevalence at a population level

303 allowed a better understanding of screening practice over time and the identification of groups of  
304 patients who are at risk of receiving no screening. Our results highlight the importance of considering  
305 regularity and comprehensiveness of screening at an individual level when evaluating screening  
306 interventions, rather than reliance on prevalence of screening at a population level.

307 We required that patients had at least one year of during the study period to reliably capture  
308 screening activity. This may mean that patients who are transiently registered, who are less likely to  
309 be screened, are not included in our results. Our analysis was exploratory in nature and while we  
310 investigated a range of factors that we hypothesised were associated with receipt of CVD risk factor  
311 screening in primary care, it is likely that many of these factors interact to produce distinct risk  
312 profiles. Furthermore, we did not investigate outcomes of screening practices and therefore cannot  
313 determine the impact that screening has on for example stopping smoking, having controlled blood  
314 pressure or starting statins, nor on the longer-term health of people with SMI. There is a need for  
315 further hypothesis-driven studies to identify groups of patients at risk of missed screening, the  
316 impact this has on cardiovascular health and into the effectiveness of physical health checks and CVD  
317 risk factor screening in this population.

### 318 [Clinical Implications](#)

319 Given the known cardiovascular health inequalities in those with SMI<sup>3-7</sup>, the finding that only half of  
320 patients with SMI had ever received screening for all six CVD risk factors is concerning. Our results  
321 suggests that while incentivisation led to an increase in the annual prevalence of screening for  
322 individual CVD risk factors, few patients received regular comprehensive screening. In 2023, the  
323 proportion of patients with SMI receiving screening for all six CVD risk factors was incentivised for  
324 the first time<sup>26,27</sup>. While data collected by NHS England for physical health checks performed in  
325 primary or secondary care suggests this has increased the prevalence of screening,<sup>28</sup>our study  
326 highlights the need to consider regularity of screening as well as differences in screening prevalence,  
327 the risk of receiving no screening and always receiving complete screening by patient characteristics.

328 We found a low prevalence of screening, and high risk of receiving no screening in those with missing  
329 ethnicity, without pre-existing conditions or of younger age. While for those with missing ethnicity,  
330 this is likely driven by lack of healthcare contact underpinning both poor ethnicity recording and low  
331 levels of screening, for those of younger age or without other physical health conditions it may be  
332 driven by additional factors, such as patient and provider perceptions of need. Further interventions  
333 are therefore required to improve uptake in these groups.

334 Incentivisation appears to confer little benefit to those outside of the incentivisation criteria. For  
335 example, we found that when cholesterol and glucose screening was incentivised for patients with  
336 SMI aged over 40, there was minimal increase in screening in those under 40, so little evidence of  
337 halo effects. Likewise, those with 'other psychoses' had a lower screening prevalence of all CVD risk  
338 factors than patients with schizophrenia or bipolar disorder. The term 'other psychoses' covers a  
339 range of psychotic diagnoses and symptoms, and is broader than the list included under QOF  
340 incentivisation. These findings highlight the careful planning needed when implementing  
341 incentivisation so that those falling outside of incentivisation but still at risk are not marginalised,  
342 particularly in those with SMI, who may develop multimorbidity at an early age<sup>1</sup>, and where formal  
343 diagnosis may be delayed.

344 People with SMI are at risk of physical health conditions beyond CVD<sup>1</sup>, and of avoidable physical  
345 health hospitalisations<sup>29</sup>. Current NHS guidance describes the incentivised CVD risk factors as core to  
346 the physical health check in primary care, but recommends a more comprehensive annual review of  
347 physical health<sup>30</sup>. We found that only a third of patients ever received screening of all six CVD risk  
348 factors within a month of each other suggesting that CVD risk factors may be captured  
349 opportunistically. While opportunistic screening results in higher screening prevalence, screening is  
350 only a first step. It is important that patients also receive a comprehensive clinical review of physical  
351 health so that coordinated actions can be put in place to manage CVD risk, and diagnose and treat  
352 conditions beyond CVD. While physical health screening is embedded in primary care, further

353 consideration is warranted as to the provision of physical health checks in mental health services to  
354 complement those in primary care and to provide services to those not regularly in contact with their  
355 primary care provider. However, this approach is reliant on improved coordination between physical  
356 and mental health care providers to avoid duplication for both patient and practitioner, and to  
357 ensure transfer of important patient information.

## 358 Conclusions

359 The low proportion of people receiving regular CVD risk factor screening suggests that people with  
360 SMI are not reliably receiving regular comprehensive physical health checks in primary care. Further  
361 consideration is warranted as to how incentivisation and other schemes could improve the regularity  
362 and comprehensiveness of screening, rather than just the annual screening prevalence, and whether  
363 provision of physical health checks in both physical and mental health services may improve up-take.  
364 Hypothesis-driven work is required to identify groups of patients most at risk of not receiving CVD  
365 risk factor screening so that targeted interventions can be developed, with consideration of these  
366 groups in the planning and implementation of future incentivisation and other improvement  
367 schemes.

## 368 References

- 369
- 370 1. Launders N, Hayes JF, Price G, Osborn DPJ. Clustering of physical health multimorbidity in people  
371 with severe mental illness: An accumulated prevalence analysis of United Kingdom primary  
372 care data. *PLoS Medicine* 2022;19(4)
  - 373 2. Firth J, Siddiqi N, Koyanagi A, et al. The Lancet Psychiatry Commission: a blueprint for protecting  
374 physical health in people with mental illness. *Lancet Psychiatry* 2019;6(8):675-712. doi:  
375 10.1016/S2215-0366(19)30132-4 [published Online First: 2019/07/22]
  - 376 3. Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular  
377 disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis  
378 of 3,211,768 patients and 113,383,368 controls. *World Psychiatry* 2017;16(2):163-80. doi:  
379 10.1002/wps.20420 [published Online First: 2017/05/13]
  - 380 4. Lambert AM, Parretti HM, Pearce E, et al. Temporal trends in associations between severe mental  
381 illness and risk of cardiovascular disease: A systematic review and meta-analysis. *PLoS*  
382 *Medicine* 2022;19(4):e1003960. doi: 10.1371/journal.pmed.1003960 [published Online First:  
383 2022/04/20]
  - 384 5. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in  
385 people with schizophrenia and related psychotic disorders, bipolar disorder and major  
386 depressive disorder: a systematic review and meta-analysis. *World Psychiatry*  
387 2015;14(3):339-47. doi: 10.1002/wps.20252 [published Online First: 2015/09/27]

- 388 6. Launderers N, Dotsikas K, Marston L, et al. The impact of comorbid severe mental illness and  
389 common chronic physical health conditions on hospitalisation: A systematic review and  
390 meta-analysis. *PLoS One* 2022;17(8):e0272498. doi: 10.1371/journal.pone.0272498  
391 [published Online First: 2022/08/19]
- 392 7. Correll CU, Ng-Mak DS, Stafkey-Mailey D, et al. Cardiometabolic comorbidities, readmission, and  
393 costs in schizophrenia and bipolar disorder: a real-world analysis. *Annals of general*  
394 *psychiatry* 2017;16:9. doi: 10.1186/s12991-017-0133-7 [published Online First: 2017/02/17]
- 395 8. Kalkhoran S, Thorndike AN, Rigotti NA, et al. Cigarette Smoking and Quitting-Related Factors  
396 Among US Adult Health Center Patients with Serious Mental Illness. *J Gen Intern Med*  
397 2019;34(6):986-91. doi: 10.1007/s11606-019-04857-3 [published Online First: 2019/02/21]
- 398 9. Afzal M, Siddiqi N, Ahmad B, et al. Prevalence of Overweight and Obesity in People With Severe  
399 Mental Illness: Systematic Review and Meta-Analysis. *Front Endocrinol (Lausanne)*  
400 2021;12:769309. doi: 10.3389/fendo.2021.769309 [published Online First: 2021/12/14]
- 401 10. Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia,  
402 bipolar disorder and major depressive disorder: a systematic review and large scale meta-  
403 analysis. *World Psychiatry* 2016;15(2):166-74. doi: 10.1002/wps.20309 [published Online  
404 First: 2016/06/07]
- 405 11. Brauer R, Douglas, I., Smeeth, L. The association between antipsychotic agents and the risk of  
406 myocardial infarction: a systematic review. *Br J Clin Pharmacol* 2011;72(6):871-78. doi:  
407 10.1111/j.1365-2125.2011.04043.x
- 408 12. McCarter R, Rosato M, Thampi A, et al. Physical health disparities and severe mental illness: a  
409 longitudinal comparative cohort study using hospital data in Northern Ireland. *Eur Psychiatry*  
410 2023;1-26. doi: 10.1192/j.eurpsy.2023.2441 [published Online First: 20230814]
- 411 13. Lee SC, DelPozo-Banos M, Lloyd K, et al. Area deprivation, urbanicity, severe mental illness and  
412 social drift - A population-based linkage study using routinely collected primary and  
413 secondary care data. *Schizophr Res* 2020;220:130-40. doi: 10.1016/j.schres.2020.03.044  
414 [published Online First: 2020/04/07]
- 415 14. NHS Digital. Quality and Outcomes Framework, 2004-05 2005 [Available from:  
416 [https://data.england.nhs.uk/dataset/qof-national-quality-outcomes-framework-2004-](https://data.england.nhs.uk/dataset/qof-national-quality-outcomes-framework-2004-05/resource/c130ad9e-06b2-47c5-ad42-eeb36b1e8740)  
417 [05/resource/c130ad9e-06b2-47c5-ad42-eeb36b1e8740](https://data.england.nhs.uk/dataset/qof-national-quality-outcomes-framework-2004-05/resource/c130ad9e-06b2-47c5-ad42-eeb36b1e8740) accessed 29/09/2022.
- 418 15. Osborn DP, Baio G, Walters K, et al. Inequalities in the provision of cardiovascular screening to  
419 people with severe mental illnesses in primary care: cohort study in the United Kingdom  
420 THIN Primary Care Database 2000-2007. *Schizophr Res* 2011;129(2-3):104-10. doi:  
421 10.1016/j.schres.2011.04.003 [published Online First: 2011/05/10]
- 422 16. Wilson CL, Rhodes KM, Payne RA. Financial incentives improve recognition but not treatment of  
423 cardiovascular risk factors in severe mental illness. *PLoS One* 2017;12(6):e0179392. doi:  
424 10.1371/journal.pone.0179392 [published Online First: 2017/06/10]
- 425 17. Hardoon SL, Khadjesari Z, Nazareth I, et al. Monitoring of alcohol consumption in primary care  
426 among adults with bipolar disorder: A cross-sectional and retrospective cohort study. *J Affect*  
427 *Disord* 2016;198:83-7. doi: 10.1016/j.jad.2016.03.019 [published Online First: 2016/03/26]
- 428 18. Khadjesari Z, Hardoon SL, Petersen I, et al. Impact of Financial Incentives on Alcohol Consumption  
429 Recording in Primary Health Care Among Adults with Schizophrenia and Other Psychoses: A  
430 Cross-Sectional and Retrospective Cohort Study. *Alcohol Alcohol* 2017;52(2):197-205. doi:  
431 10.1093/alcalc/agw076 [published Online First: 2017/02/10]
- 432 19. Matias MA, Jacobs R, Aragon MJ, et al. Assessing the uptake of incentivised physical health  
433 checks for people with serious mental illness. *British Journal of General Practice* 2024 doi:  
434 10.3399/BJGP.2023.0532 [published Online First: 20240208]
- 435 20. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research  
436 Datalink (CPRD). *International Journal of Epidemiology* 2015;44(3):827-36. doi:  
437 10.1093/ije/dyv098 [published Online First: 2015/06/08]

- 438 21. Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink  
439 (CPRD) Aurum. *International Journal of Epidemiology* 2019;48(6):1740-40g. doi:  
440 10.1093/ije/dyz034 [published Online First: 2019/03/13]  
441 22. NHS Employers. Quality and Outcomes Framework 2016 [Available from:  
442 <https://webarchive.nationalarchives.gov.uk/ukgwa/20160512105008/http://www.nhsemployers.org/your-workforce/primary-care-contacts/general-medical-services/quality-and-outcomes-framework>.  
443  
444  
445 23. ONS. 2011 Census Variable and Classification Information: Part 4 - derived variables: Office for  
446 National Statistics,, 2014.  
447 24. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using  
448 Observational Routinely-collected health Data (RECORD) statement. *PLoS Medicine*  
449 2015;12(10):e1001885. doi: 10.1371/journal.pmed.1001885 [published Online First:  
450 20151006]  
451 25. Kontopantelis E, Springate D, Reeves D, et al. Withdrawing performance indicators: retrospective  
452 analysis of general practice performance under UK Quality and Outcomes Framework. *BMJ*  
453 2014;348:g330. doi: 10.1136/bmj.g330 [published Online First: 20140127]  
454 26. NHS England. Quality and Outcomes Framework guidance for 2023/24 2023 [Available from:  
455 <https://www.england.nhs.uk/publication/quality-and-outcomes-framework-guidance-for-2023-24/>.  
456  
457 27. NHS England. The NHS Long Term Plan: NHS England, 2019.  
458 28. NHS England. Physical Health Checks for people with Severe Mental Illness 2022 [Available from:  
459 <https://www.england.nhs.uk/statistics/statistical-work-areas/serious-mental-illness-smi/>  
460 accessed 30/09/2022.  
461 29. Launders N, Hayes JF, Price G, et al. The incidence rate of planned and emergency physical health  
462 hospital admissions in people diagnosed with severe mental illness: a cohort study.  
463 *Psychological Medicine* 2022:1-12. doi: 10.1017/S0033291722002811 [published Online  
464 First: 2022/09/08]  
465 30. NHS England. Improving the physical health of people living with severe mental illness 2024  
466 [Available from: <https://www.england.nhs.uk/long-read/improving-the-physical-health-of-people-living-with-severe-mental-illness/>.  
467  
468 31. Department of Health NI. Quality and Outcomes Framework (QOF) 2022 [Available from:  
469 <https://www.health-ni.gov.uk/topics/doh-statistics-and-research/quality-outcomes-framework-qof> accessed 29/09/2022.  
470  
471 32. Welsh Government. General Medical Services Contract Quality and Outcomes Framework  
472 Statistics for Wales, 2018-2019, 2019.  
473 33. Welsh Government. General Medical Services Contract: Quality and Outcomes Framework  
474 Statistics for Wales, 2014-15, 2015.  
475 34. Public Health Scotland. Quality and Outcomes Framework: 2014/2015 Achievement at Scotland  
476 and NHS Board Level, 2015.  
477 35. Department of Health NI. Quality and outcomes framework (QOF) achievement data 2014/15,  
478 2015.

479



## 480 Funding statement

481 This work was funded by the HDR UK DATAMIND hub, which is funded by the UK Research and  
482 Innovation grant MR/W014386/1. NL, JFH, MHI, EB RS, AJ and DPJO acknowledge funding from  
483 DATAMIND.

484

485 NL is additionally supported by a Health Data Research UK personal fellowship. This work is affiliated  
486 to Health Data Research UK (Big Data for Complex Disease- HDR-23012), which is funded by the  
487 Medical Research Council (UKRI), the National Institute for Health Research, the British Heart  
488 Foundation, Cancer Research UK, the Economic and Social Research Council (UKRI), the Engineering  
489 and Physical Sciences Research Council (UKRI), Health and Care Research Wales, Chief Scientist Office  
490 of the Scottish Government Health and Social Care Directorates, and Health and Social Care Research  
491 and Development Division (Public Health Agency, Northern Ireland).

492 NL & JF are additionally supported by the UK Research and Innovation grant MR/V023373/1. NL, JFH,  
493 EB & DPJO are supported by the University College London Hospitals NIHR Biomedical Research  
494 Centre, and NL, JFH & DPJO by the NIHR North Thames Applied Research Collaboration. This funder  
495 had no role in study design, data collection, data analysis, data interpretation, or writing of the  
496 report. The views expressed in this article are those of the authors and not necessarily those of the  
497 NHS, the NIHR, or the Department of Health and Social Care.

498

499 RS is additionally part-funded by: the NIHR Maudsley Biomedical Research Centre at the South  
500 London and Maudsley NHS Foundation Trust and King's College London; the National Institute for  
501 Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at  
502 King's College Hospital NHS Foundation Trust; the UK Prevention Research Partnership (Violence,  
503 Health and Society; MR-VO49879/1), an initiative funded by UK Research and Innovation Councils,  
504 the Department of Health and Social Care (England) and the UK devolved administrations, and  
505 leading health research charities.

506 MHI is additionally supported by the Wellcome Trust (220857/Z/20/Z; 226770/Z/22/Z,  
507 104036/Z/14/Z; 216767/Z/19/Z) and by a Research Data Scotland Accelerator Award (RAS-24-2).

508 EB acknowledges the additional support of: Medical Research Council (G1100583, MR/W020238/1),  
509 National Institute of Health Research (NIHR200756), Mental Health Research UK - John Grace QC  
510 Scholarship 2018, Economic Social Research Council's Co-funded doctoral award, The British Medical  
511 Association's Margaret Temple Fellowship, Medical Research Council New Investigator and Centenary  
512 Awards (G0901310, G1100583), NIHR BRC at UCLH (Biomedical Research Centre at University College  
513 London Hospitals NHS Foundation Trust and University College London).

## 514 Conflicts of interest

515 JFH has received consultancy fees from juli Health and Wellcome. He is a co-founder and shareholder  
516 of juli Health. juli Health has a patent pending. RS declares research support received in the last 3  
517 years from GSK and Takeda.

## 518 Data sharing statement

519 Data were obtained from a third party and are not publicly available. All data were obtained from  
520 Clinical Practice Research Datalink (CPRD). Data is available from CPRD but is subject to protocol  
521 approval and ethical review: <https://www.cprd.com/research-applications>.

## 522 Acknowledgments

523 The authors wish to acknowledge the input from the wider collaborators involved in DATAMIND, and  
524 particularly the input from lived experience advisors.

525 [Author contributions](#)

526 NL wrote the protocol, analysed the data and wrote the first draft of the manuscript. JFH and DPJO  
527 had oversight of the data and contributed to the initial study design. CAJ, JFH, AJ, RS, MHI, EB and  
528 DPJO commented on the study protocol and helped formulate the original research question. All  
529 authors provided input on the interpretation of results and commented on the first draft of the  
530 manuscript.